BrightEdge is the innovation, impact investment and venture capital arm of the American Cancer Society. Today, our ACS Impact Venture Fund (AIVF) invests in for-profit, early-stage companies developing cutting-edge, cancer-focused therapeutics, diagnostics, devices, and technologies to fuel and accelerate ACS’s mission of ending cancer as we know it, for everyone.
We create equitable access to capital by developing community partnerships and innovative financial products, services and tools that tackle systemic challenges and advance promising opportunities for residents and businesses in economically distressed communities.
